Aarey Drugs & Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Aarey Drugs & Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 17.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Earnings Not Telling The Story For Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) After Shares Rise 46%
Aug 30
Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) Shares May Have Run Too Fast Too Soon
Jul 16Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Apr 15Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) Has A Pretty Healthy Balance Sheet
Mar 22What Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) P/E Is Not Telling You
Dec 30Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Shares Fly 25% But Investors Aren't Buying For Growth
Dec 29Calculating The Fair Value Of Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS)
Aug 20In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aarey Drugs & Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 5,189 | 60 | -19 | -3 | N/A |
| 6/30/2024 | 4,716 | 52 | N/A | N/A | N/A |
| 3/31/2024 | 3,956 | 47 | -37 | -30 | N/A |
| 12/31/2023 | 3,481 | 29 | N/A | N/A | N/A |
| 9/30/2023 | 3,341 | 24 | -2 | 3 | N/A |
| 6/30/2023 | 3,511 | 37 | N/A | N/A | N/A |
| 3/31/2023 | 4,190 | 38 | -23 | -13 | N/A |
| 12/31/2022 | 3,768 | 27 | N/A | N/A | N/A |
| 9/30/2022 | 4,542 | 41 | -67 | -58 | N/A |
| 6/30/2022 | 5,169 | 48 | N/A | N/A | N/A |
| 3/31/2022 | 4,929 | 66 | -17 | 5 | N/A |
| 12/31/2021 | 5,537 | 87 | N/A | N/A | N/A |
| 9/30/2021 | 5,068 | 85 | -27 | 17 | N/A |
| 6/30/2021 | 4,277 | 77 | N/A | N/A | N/A |
| 3/31/2021 | 3,514 | 65 | 26 | 55 | N/A |
| 12/31/2020 | 2,838 | 61 | N/A | N/A | N/A |
| 9/30/2020 | 2,462 | 58 | N/A | N/A | N/A |
| 6/30/2020 | 2,591 | 51 | N/A | N/A | N/A |
| 3/31/2020 | 3,009 | 58 | 19 | 29 | N/A |
| 12/31/2019 | 3,282 | 55 | N/A | N/A | N/A |
| 9/30/2019 | 3,470 | 57 | N/A | N/A | N/A |
| 6/30/2019 | 3,536 | 65 | N/A | N/A | N/A |
| 3/31/2019 | 3,562 | 65 | -5 | 7 | N/A |
| 12/31/2018 | 3,343 | 66 | N/A | N/A | N/A |
| 9/30/2018 | 3,454 | 69 | N/A | N/A | N/A |
| 6/30/2018 | 3,429 | 64 | N/A | N/A | N/A |
| 3/31/2018 | 3,493 | 62 | N/A | -204 | N/A |
| 12/31/2017 | 3,554 | 67 | N/A | N/A | N/A |
| 9/30/2017 | 3,619 | 67 | N/A | N/A | N/A |
| 6/30/2017 | 3,751 | 67 | N/A | N/A | N/A |
| 3/31/2017 | 3,960 | 55 | N/A | 6 | N/A |
| 12/31/2016 | 3,817 | 46 | N/A | N/A | N/A |
| 9/30/2016 | 3,490 | 30 | N/A | N/A | N/A |
| 6/30/2016 | 2,988 | 18 | N/A | N/A | N/A |
| 3/31/2016 | 2,460 | 13 | N/A | 57 | N/A |
| 12/31/2015 | 2,146 | 13 | N/A | N/A | N/A |
| 9/30/2015 | 2,040 | 13 | N/A | N/A | N/A |
| 6/30/2015 | 2,207 | 11 | N/A | N/A | N/A |
| 3/31/2015 | 2,134 | 11 | N/A | 33 | N/A |
| 12/31/2014 | 1,732 | 8 | N/A | N/A | N/A |
| 9/30/2014 | 1,788 | 9 | N/A | N/A | N/A |
| 6/30/2014 | 1,874 | 14 | N/A | N/A | N/A |
| 3/31/2014 | 1,997 | 11 | N/A | -4 | N/A |
| 12/31/2013 | 2,118 | 8 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if AAREYDRUGS's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if AAREYDRUGS's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if AAREYDRUGS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if AAREYDRUGS's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if AAREYDRUGS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AAREYDRUGS's Return on Equity is forecast to be high in 3 years time